Norinchukin Bank The Acquires 38,669 Shares of Pfizer Inc. $PFE

Key Points

• Norinchukin Bank increased its stake in Pfizer Inc. by 15.2%, acquiring an additional 38,669 shares during the first quarter, bringing its total holdings to 293,066 shares worth approximately $7.426 million.
• Pfizer reported an earnings per share of $0.78 for the last quarter, exceeding expectations and achieving a 10.3% year-over-year revenue increase.
• The company declared a quarterly dividend of $0.43 per share, with a 6.8% dividend yield, scheduled for payment on September 2nd.

Norinchukin Bank The increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 293,066 shares of the biopharmaceutical company's stock after acquiring an additional 38,669 shares during the quarter. Norinchukin Bank The's holdings in Pfizer were worth $7,426,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Clarity Asset Management Inc. bought a new position in Pfizer during the fourth quarter worth $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in Pfizer during the first quarter worth $27,000. North Capital Inc. bought a new position in Pfizer during the first quarter worth $28,000. Finally, Bayforest Capital Ltd bought a new position in Pfizer during the first quarter worth $28,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 0.2%

Shares of PFE stock opened at $25.3750 on Thursday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a 50-day simple moving average of $24.66 and a two-hundred day simple moving average of $24.42. The company has a market capitalization of $144.27 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 0.90 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is 91.49%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Bank of America increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Redburn Atlantic lowered their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group upped their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Leerink Partners lowered their price objective on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.